drugset / Trial / NCT02279511

ATP in Alzheimer Disease

NCT02279511

Phase 2 Completed 20 enrolled Sara Varea
RandomizedParallel-groupTriple-blindOther

Summary

To Check whether systemic treatment with ATP alters the profile of cerebral metabolism in patients with Alzheimer's disease using MRS techniques (Magnetic Resonance Spectroscopy) and adjust the infusion (minimum effective dose) that promotes this metabolic change.

Timeline

Start
2014-12
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject adenosine triphosphate Small molecule 2.5 g

Indications